PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.267
EU - Europa 9.913
AS - Asia 2.668
AF - Africa 70
SA - Sud America 55
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 21
Totale 26.038
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.194
IT - Italia 3.028
IE - Irlanda 2.144
GB - Regno Unito 1.842
CN - Cina 875
SE - Svezia 836
DE - Germania 745
HK - Hong Kong 500
SG - Singapore 392
UA - Ucraina 345
FR - Francia 218
TR - Turchia 214
FI - Finlandia 209
BG - Bulgaria 164
IN - India 145
VN - Vietnam 117
ID - Indonesia 113
JP - Giappone 65
CA - Canada 64
TW - Taiwan 56
LT - Lituania 52
BE - Belgio 50
AU - Australia 42
MY - Malesia 38
ES - Italia 37
IQ - Iraq 36
RU - Federazione Russa 36
IR - Iran 34
CZ - Repubblica Ceca 33
EG - Egitto 32
NL - Olanda 28
KR - Corea 27
CH - Svizzera 21
BR - Brasile 20
PL - Polonia 18
EU - Europa 17
RO - Romania 17
CL - Cile 14
PK - Pakistan 13
GR - Grecia 11
AL - Albania 10
AR - Argentina 10
PH - Filippine 10
DK - Danimarca 8
ET - Etiopia 8
MK - Macedonia 8
NG - Nigeria 8
SI - Slovenia 8
HU - Ungheria 7
MT - Malta 6
MX - Messico 6
AE - Emirati Arabi Uniti 5
GH - Ghana 5
IL - Israele 5
LV - Lettonia 5
PT - Portogallo 5
CO - Colombia 4
KE - Kenya 4
NO - Norvegia 4
SA - Arabia Saudita 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TZ - Tanzania 4
AP - ???statistics.table.value.countryCode.AP??? 3
BD - Bangladesh 3
CR - Costa Rica 3
EC - Ecuador 3
HR - Croazia 3
IS - Islanda 3
AT - Austria 2
BH - Bahrain 2
BO - Bolivia 2
LY - Libia 2
MA - Marocco 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
IM - Isola di Man 1
LB - Libano 1
LK - Sri Lanka 1
MC - Monaco 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MZ - Mozambico 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
ZA - Sudafrica 1
ZM - Zambia 1
Totale 26.038
Salva come PNG Salva come JPEG
Città #
Dublin 2.139
Fairfield 1.746
Chandler 1.418
Southend 1.323
Ashburn 1.095
Woodbridge 1.005
Houston 759
Dearborn 731
Seattle 697
Nyköping 666
Ann Arbor 664
Jacksonville 601
Wilmington 592
Cambridge 530
Hong Kong 479
Beijing 313
Singapore 291
Modena 266
New York 263
Milan 246
San Diego 176
Princeton 172
Rome 171
Sofia 163
Helsinki 144
Eugene 140
Izmir 129
Shanghai 117
Bologna 110
Dong Ket 110
Jakarta 110
Redwood City 103
Fremont 100
Bremen 76
London 73
Falls Church 61
Naples 43
Norwalk 43
Parma 43
Guangzhou 41
Boardman 40
Brussels 40
Turin 37
Reggio Emilia 35
San Giuliano Milanese 34
Enfield 32
Genoa 31
Nanjing 31
Bari 30
Des Moines 30
Los Angeles 29
Ottawa 29
Phoenix 29
Padova 28
Palermo 27
Hefei 26
Catania 23
Florence 23
Baghdad 22
Lansdale 22
Tokyo 22
Asyut 21
Brno 21
Paris 21
San Mateo 21
Munich 20
Vicenza 20
Kunming 19
Dallas 18
Mumbai 18
Pisa 17
Verona 17
Chicago 16
Fulham 15
Taipei 15
Wuhan 15
Banqiao 14
Brescia 14
Frankfurt am Main 14
Toronto 14
Absecon 13
Amsterdam 13
Chiswick 13
Hyderabad 13
Sassuolo 13
Nanchang 12
Napoli 12
Perugia 12
Rimini 12
Bangalore 11
Madrid 11
New Taipei 11
Brooklyn 10
Monza 10
Piacenza 10
Stockholm 10
Sydney 10
Athens 9
Barcelona 9
Bergamo 9
Totale 19.122
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 638
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 376
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 311
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 296
GD2 expression in breast cancer. 288
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 282
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 279
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 271
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 266
Abemaciclib: eventi avversi e riduzione di dose. 254
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 253
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 251
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 246
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 245
Oxford Manuale di Medicina Clinica 244
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 242
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 241
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 239
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. 233
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 219
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 218
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 217
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 217
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 216
Tumor Stroma Manipulation By MSC 215
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 210
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 209
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 208
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 202
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 202
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 200
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 199
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 197
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 194
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 193
Immune characterization of breast cancer metastases: prognostic implications. 193
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 191
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 189
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 189
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 188
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 187
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 186
Achievements and unmet needs in the management of advanced ovarian cancer 185
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 184
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 184
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 183
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 183
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 182
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 182
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 181
Prognostic Factors for Breast Cancer: an Immunomorphological Update 181
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 181
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 181
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 180
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 180
Timing for starting second line therapy in recurrent ovarian cancer. 179
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 175
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 173
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 171
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 171
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 170
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 169
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 167
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 165
Breast Location for De Novo Extramedullary Myeloid Sarcoma 165
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 162
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 161
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 158
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 157
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 154
Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: biomarker analyses of the randomized phase II LET-LOB study 152
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 152
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 152
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 150
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 150
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 149
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 147
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 146
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 145
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 142
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 142
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 142
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 141
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 141
Lapatinib and renal impairment: a case report 139
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 138
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 137
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 136
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 136
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 134
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. 130
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 130
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 127
Tumor infiltrating lymphocytes and correlation with pCR in ther CHERLOB study 127
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 127
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 127
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 126
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 126
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 125
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 125
Totale 19.099
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.883
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.811 0 0 189 265 490 680 824 382 383 177 272 149
2020/20214.250 422 199 256 329 479 369 364 454 265 463 344 306
2021/20223.322 133 382 286 128 122 259 150 198 363 298 591 412
2022/20236.445 490 580 338 414 409 511 111 387 2.557 114 324 210
2023/20243.715 179 202 238 291 496 314 340 568 150 204 296 437
2024/2025698 356 209 133 0 0 0 0 0 0 0 0 0
Totale 26.402